The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LNTH | -48.52% | +343.5% | +34.7% | +797% |
| S&P | +15.06% | +95.03% | +14.29% | +220% |
Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and Puerto Rico, third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America, and the EXINI business in Sweden. The company was founded in 1956 and is headquartered in Bedford, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $378.05M | -4.1% |
| Gross Profit | $241.01M | -5.8% |
| Gross Margin | 63.75% | -1.2% |
| Market Cap | $5.66B | 1.8% |
| Market Cap / Employee | $7.01M | 0.0% |
| Employees | 808 | -3.1% |
| Net Income | $78.76M | 26.9% |
| EBITDA | $101.20M | -13.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $695.57M | -8.1% |
| Accounts Receivable | $336.58M | -9.6% |
| Inventory | 62.2 | -11.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $614.70M | -0.4% |
| Short Term Debt | $0.80M | -73.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 13.36% | -12.8% |
| Return On Invested Capital | 6.19% | 1.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $79.15M | 7.6% |
| Operating Free Cash Flow | $87.11M | 2.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 18.24 | 20.46 | 27.70 | 21.74 | 65.41% |
| Price to Book | 6.59 | 5.37 | 6.36 | 4.86 | -18.93% |
| Price to Sales | 5.36 | 4.04 | 4.54 | 3.79 | -3.98% |
| Price to Tangible Book Value | 8.23 | 6.71 | 8.00 | 5.96 | -21.95% |
| Price to Free Cash Flow TTM | 17.74 | 12.62 | 14.82 | 12.08 | -15.82% |
| Enterprise Value to EBITDA | 51.54 | 46.68 | 57.48 | 56.09 | 19.08% |
| Free Cash Flow Yield | 5.6% | 7.9% | 6.7% | 8.3% | 18.80% |
| Return on Equity | 45.5% | 32.8% | 24.1% | 24.7% | -54.46% |
| Total Debt | $621.30M | $621.31M | $614.40M | $615.49M | -0.77% |
LNTH earnings call for the period ending September 30, 2021.
LNTH earnings call for the period ending June 30, 2021.
LNTH earnings call for the period ending March 31, 2021.
LNTH earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
